









Markets
/
Stocks
/
nasdaq-aneb
/

Anebulo Pharmaceuticals Inc

ANEB

2.530USD

-0.010-0.39%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

103.94MMarket Cap

LossP/E TTM



Anebulo Pharmaceuticals Inc

2.530

-0.010-0.39%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Anebulo Pharmaceuticals Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Anebulo Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

271 / 501

Overall Ranking

486 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Hold

Current Rating

8.000

Target Price

+220.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Anebulo Pharmaceuticals Inc Highlights

StrengthsRisks

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous treatment. Selonabant has completed dosing in a Phase II clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. It is also prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with unintentional cannabis poisoning.

Undervalued

The company’s latest PE is -10.76, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 22.59M shares, decreasing 1.33% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 215.95K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.47.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Anebulo Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.58, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -10.76, which is -100.00% below the recent high of 0.00 and -21.94% above the recent low of -13.12.

Score

Industry at a Glance

Previous score

6.58

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 271/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 6.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Anebulo Pharmaceuticals Inc is 8.00, with a high of 8.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts

Hold

Current Rating

8.000

Target Price

+220.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Anebulo Pharmaceuticals Inc

ANEB

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 6.46, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.96 and the support level at 2.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.13

Change

1.33

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.038

Neutral

RSI(14)

47.373

Neutral

STOCH(KDJ)(9,3,3)

22.747

Sell

ATR(14)

0.120

Low Volatility

CCI(14)

-148.673

Sell

Williams %R

86.486

Oversold

TRIX(12,20)

0.450

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.612

Sell

MA10

2.667

Sell

MA20

2.587

Sell

MA50

2.481

Buy

MA100

2.304

Buy

MA200

1.777

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 54.99%, representing a quarter-over-quarter decrease of 42.47%. The largest institutional shareholder is The Vanguard, holding a total of 215.95K shares, representing 0.53% of shares outstanding, with 40.20% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

22NW, LP

15.47M

Lawler (Joseph F.)

12.00M

English (Aron R)

4.65M

Nantahala Capital Management, LLC

3.04M

Mangrove Partners

2.53M

Morgan Stanley & Co. LLC

399.22K

The Vanguard Group, Inc.

Star Investors

215.95K

+5.58%

Geode Capital Management, L.L.C.

205.72K

+0.15%

Ikarian Capital LLC

157.72K

Millennium Management LLC

153.81K

-3.24%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.89. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.